Inherent Biosciences has announced its initial capital raise led by Morning Star Foundation with additional participation from MedMountain Ventures, Kickstart Funds, Park City Angels, Rhythm VC and several angel investors. With the initial funding, Inherent will launch a male infertility diagnostic to guide infertility treatment.
Inherent also added following members to its Board of Directors and Clinical Advisors: Lewis Rumpler – Former CEO of Epigenesys, Executive Chairman, Saumitra Thakur, MD – MedMountain Ventures, Director, David Shriner – Morning Star Foundation, Director, Tia Newcomer – Independent Director, Tom Simpson – Kick Start Funds, Board Observer, Doug Carrell, PhD, HCLD – Andrology Advisor, Paul Turek, MD – Clinical Advisor, Larry Lipshultz, MD – Clinical Advisor.
“We’ve been impressed with Inherent’s team and the intellectual property portfolio they’ve assembled,” said David Shriner, Chairman at Morning Star Foundation. “By leveraging artificial intelligence and machine learning within the field of epigenetics, Inherent has developed an exciting pipeline of novel diagnostics to help millions of people suffering from unexplained medical conditions.”
Inherent Biosciences, Inc. is a molecular diagnostics company at the intersection of epigenetics and AI.
